Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

In chronic-phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib, failure to achieve early molecular response (EMR; EMR failure: BCR-ABL1 >10% on the international scale at 3 months) is predictive of inferior outcomes. Identifying patients at high-risk of EMR failure at...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Kok, Chung H., Yeung, David T., Lu, Liu, Watkins, Dale B., Leclercq, Tamara M., Dang, Phuong, Saunders, Verity A., Reynolds, John, White, Deborah L., Hughes, Timothy P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538873/
https://ncbi.nlm.nih.gov/pubmed/31126916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000195
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados